NXTC (NextCure) Margin of Safety % (DCF FCF Based) : N/A (As of Jan. 18, 2025)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

NextCure's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of NextCure's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, NextCure's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCure's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where NextCure's Margin of Safety % (DCF FCF Based) falls into.

NextCure Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of NextCure's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (NAS:NXTC) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

2US:Germany

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.

Executives

Anne Elizabeth Borgman	director	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Ellen Feigal	director	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Kevin G. Shaw	officer: Sr VP, Legal Affairs	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sourav Kundu	officer: Sr VP, Dev. & Mfg.	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Han Myint	officer: Chief Medical Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Timothy Mayer	officer: Chief Operating Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sol Langermann	officer: Chief Scientific Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Steven P. Cobourn	officer: Chief Financial Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Linda Liu	officer: SVP, Research	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Michael Richman	director, officer: President & CEO	2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
John G Houston	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anand Mehra	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Powell	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025